{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-228331","form_type":"8-K/A","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.207463+00:00","generated_at":"2026-05-17T04:58:11.090425+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"enGene Holdings appoints Astley-Sparke and Heffernan to board committees","bullets":["Philip Astley-Sparke appointed to Audit Committee and Nominating & Corporate Governance Committee.","Michael Heffernan appointed to Audit Committee and Compensation Committee.","Committee assignments effective October 2, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-228331","json":"https://secwatch.observer/filing/0001193125-25-228331.json","markdown":"https://secwatch.observer/filing/0001193125-25-228331.md","text":"https://secwatch.observer/filing/0001193125-25-228331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312525228331/0001193125-25-228331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312525228331/engn-20250707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:58:11.090425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}